Abstract
Adjuvant systemic therapy has contributed to a significant improvement of disease-free and overall survival in addition to surgery and irradiation to the local disease. The adjuvant therapy to a patient is determined integrating the information on estimated risk of recurrence, benefit and harm of the therapy and the patient's value. In this review, the state of the art of adjuvant therapy is discussed from several aspects, such as interpretation and evaluation of risk, the best available evidences on adjuvant systemic therapy, the future direction of primary therapy for breast cancer, and patient-oriented decision making.
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Cisplatin / administration & dosage
-
Clinical Trials as Topic
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Lymphatic Metastasis
-
Mastectomy
-
Methotrexate / administration & dosage
-
Neoplasm Recurrence, Local / epidemiology
-
Prognosis
-
Survival Rate
-
Tamoxifen / therapeutic use*
-
Tegafur / administration & dosage
-
Uracil / administration & dosage
Substances
-
Antineoplastic Agents, Hormonal
-
Tamoxifen
-
Tegafur
-
Uracil
-
Cisplatin
-
Fluorouracil
-
Methotrexate
Supplementary concepts
-
1-UFT protocol
-
CMF protocol